RCE at the 17th Annual Biomarkers Symposium
Mar 25, 2023
2 min read
0
4
0
Torrey Pines, California (March 25, 2023)
The 17th Annual Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium showcased the latest clinical data, guidelines and evidence related to the clinical application of novel biomarkers in cardiovascular conditions.
Topics covered state-of-the-art application of biomarkers in current standards in the prediction, diagnosis and management of cardiovascular diseases, highly sensitive troponin testing and the evolution of this novel biomarker in diagnosing and managing acute myocardial infarction and other cardiovascular conditions. The use of biomarkers was emphasized as key components of precision medicine in cardiovascular diseases.
The symposium expanded the definition of the biomarker beyond the conventional notion of a protein, or a specific analyte. References to Chat-GPT's definition of the biomarker were the highlight throughout the conference:
"A biomarker is a measurable characteristic or substance in an organism that indicates the presence of a disease, infection, or a particular physiological or pathological process. Biomarkers can be found in various body fluids, such as blood, urine, and cerebrospinal fluid, or in tissues, such as tumors or biopsied tissues.
Biomarkers can also be used to evaluate the effectiveness of a treatment or to predict the likelihood of disease development or recurrence. Examples of biomarkers include levels of specific proteins or enzymes, genetic mutations or variations, and imaging features such as the size and shape of a tumor."
Various evidence-based biomarker data were presented with references from peer reviewed literature that spanned across cardiovascular, endocrine, renal, pulmonary and related diseases. RCE presented its early findings from the normal range FDA study, at the case studies and poster exhibits. This work is accepted to the Biomarkers journal.
Download the poster PDF here:
About RCE.ai:RCE.ai, an innovative artificial intelligence (AI) based medical technology company launched in Carlsbad, Calif., in 2018, is dedicated to early heart attack detection. The company has revolutionized the monitoring of cardiac injury by introducing Infrasensor™, a non-invasive infrared-based wearable device. RCE’s proprietary transdermal approach, enhanced with deep learning techniques, analyzes and associates unique optical signatures with cardiac conditions in real-time. This AI-coupled transdermal approach enables the potential application of RCE’s technology in various emergency care settings and remote monitoring applications. Presently, RCE is engaged in clinical studies to optimize the Infrasensor for clinical use. Through ongoing clinical studies, the company hopes to soon secure FDA approval for its technology, opening the door to making it available for sale in the United States.
For more information, please visit https://rce.ai/contact, follow us on LinkedIn or X (formerly Twitter), or contact RCE Investor Relations at ir@rce.ai
Related Posts
